Matt Lehman brings significant biopharma industry experience, particularly in cell therapy development, regulatory strategy, intellectual property management, negotiating grants and incentives, and raising capital for R&D stage companies. He is an experienced international entrepreneur, having started or turned around businesses in the U.S., Australia, Ukraine, Germany, and Canada. Matt has served as an executive and a board director for public companies listed on NASDAQ, ASX, CSE, and OTCQB.
Matt established Legato Therapeutics in March 2016 to commercialize pancreatic islet transplant technologies. Along with Legato’s co-founders from the University of Louisville, the company started commercial operations and sales of Kyslecel™ in November 2017 for the treatment of chronic pancreatitis. Matt then led Legato’s first capital raise in early 2018 to fund Legato’s growth.
Previously, Matt served as interim CEO of M Pharmaceutical, Inc. (CSE and OTC), now Callitas Therapeutics, Inc., where he led a turnaround to revamp the company’s technology pipeline. He was the CEO of Prima Biomed Ltd, a dual-listed public company (NASDAQ and ASX) developing cellular immunotherapies for cancer, where he obtained “Fast Track” from the FDA and “Orphan Drug” designation for Prima Biomed’s lead product at the time. He was also Chief Operating Officer of SPRI Clinical Trials, a global contract research organization, conducting dozens of clinical trials in various fields, including pivotal trials for now marketed therapeutics such as Lyrica®, RAVICTI®, and removab®.
A graduate of Columbia University (MS) and University of Louisville (BA), Matt recently returned to his native Kentucky. Outside of the office, he enjoys spending time with family, travel, reading, basketball, and horse racing.